Should I buy Resmed stock in 2025?

Why trust HelloSafe?

At HelloSafe, our specialist has been monitoring Resmed's performance for more than three years. Each month, hundreds of thousands of Australians rely on our insights to help them understand market trends and uncover the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical standards, we have never been, and will never be, paid by Resmed.

What is Resmed?

How much is Resmed stock?

The price of Resmed stock is rising this week. As of now, Resmed shares are trading at $239.95, marking a 1.46% gain in the last 24 hours and a 1.73% increase over the week. The company holds a market capitalisation of $35.18 billion, supported by an average three-month daily volume of 1.13 million shares.

The stock trades at a P/E ratio of 26.93, offers a dividend yield of 0.88%, and has a beta of 0.75, indicating relatively low volatility compared to the broader market. With its strong fundamentals and steady upward movement, Resmed presents an appealing option for investors seeking growth with moderate risk.

Our full analysis on Resmed stock

We have conducted a deep-dive analysis of ResMed Inc. (RMD) by reviewing its latest financial results, tracking the stock’s performance over the past three years, and factoring in comparative sector data. By leveraging proprietary algorithms that synthesise ResMed’s financial metrics, technical signals, market dynamics, and competitive positioning, we offer a comprehensive perspective on the stock’s current status. So, why might ResMed stock once again become a strategic entry point into the healthcare technology sector in 2025?

Recent Performance and Market Context

ResMed shares have displayed both resilience and strength, trading as of May 3, 2025, at $239.95 with an intraday uptick of 1.46%. Over the past year, the stock is up a robust 10.59%, and while the prior six months saw a modest retracement of -1.77%, recent price action and positive company-specific developments signal renewed momentum. Notably, the consensus analyst target price sits at $311.94, indicating an upside of more than 30% and reflecting sustained bullish sentiment.

• Acquisition of VirtuOx (May 2025): The addition of VirtuOx broadens ResMed’s diagnostic toolkit, fortifying its leadership in the lucrative and expanding sleep and respiratory care market.
• NightOwl™ Nationwide Launch: The rollout of the NightOwl™ home sleep apnea test across the US unlocks new consumer channels and diversifies revenue streams.
• Research Leadership: Landmark clinical research, recently published in The Lancet Respiratory Medicine, cements ResMed’s position as a thought leader and bolsters physician and patient trust.

At the macro level, the demand for sleep and respiratory health solutions continues to trend upward. The global sleep apnea devices market is projected to expand at a 7.3% CAGR to $9.3 billion by 2029, creating a favourable tailwind. Persistent supply chain normalisation, a stable regulatory backdrop, and rising public health awareness about sleep disorders further strengthen the sector’s proposition for potential investors.

Technical Analysis

• Relative Strength Index (RSI 14): At 65.63, the RSI points to strong, but not overextended, buying interest.
• MACD (12,26,9): Positive at 3.04, reinforcing bullish momentum.
• Moving Averages:
• The current price stands convincingly above the 20-day ($220.76), 50-day ($220.90), 100-day ($229.05), and 200-day ($233.01) moving averages—reflecting sustained upward momentum and confirming a positive medium-term trend.
• Support & Resistance:
• Robust support exists at $237.70, with additional cushions at $227.20–$230.21 and $217.99–$223.62. Key resistance is found immediately at $240.48, and a significant breakout could propel the stock towards the $252.92–$257.66 range.

This technical structure is particularly favourable: with the price consolidating above all critical moving averages and maintaining volume on advances, the chart configuration suggests accumulating interest at current levels. Short-term corrections have been met by buyers at key supports, while the medium-term set-up argues for a new phase of upside potential if resistance zones are cleared.

Fundamental Analysis

• Revenue: At $1.29 billion, revenues grew by 8% year-over-year (9% in constant currency), outpacing sector averages and underscoring robust demand.
• Profitability: Net income surged 21% year-over-year to $365 million; diluted EPS soared 22% to $2.48. The operating margin reflects disciplined cost control and pricing power.
• Margins: Gross margin expanded to 59.3%, improved by 140 basis points—evidence of successful product mix optimisation and supply chain management.
• Cash Generation: Operating cash flow of $579 million positions the company well for continued R&D investment, strategic acquisitions, and dividend stability.

Valuation remains reasonable in light of growth prospects:

• P/E Ratio: At 26.93, the multiple sits at a premium to the market but is well-justified for a sector leader with above-average profitability and secular growth.
• Yield: A steady 0.88% dividend yield with a recent payout increase signals confidence in future cash flows.
• PEG and Price/Sales: Both ratios imply that ResMed’s earnings growth expectations are not fully reflected in current pricing, offering room for rerating as fundamentals play out.

• Global market leadership (holding ~62% share in sleep apnea treatment)
• A diversified and innovation-rich product pipeline (including software-enabled and AI-driven health platforms)
• The ability to scale addressable markets through geographic expansion and digital integration
• Strong, enduring brand standing with over three decades of clinical trust

These factors suggest the current valuation does not fully capture ResMed’s long-term earnings power and secular opportunity in the global shift towards data-driven, at-home healthcare.

Volume and Liquidity

ResMed’s trading pattern points to strong market confidence. The average daily volume stands at 1.13 million shares, with a public float of 145.58 million, allowing institutional and retail investors alike to gain exposure without liquidity constraints. Activity levels are consistent with a stock that features in major healthcare indices and ETFs—a sign of dynamic market validation and robust secondary trading. This broad participation tends to support a dynamic and fair valuation, particularly as volume surges on positive corporate news.

Catalysts and Positive Outlook

• Innovative Product Rollouts: With the nationwide launch of NightOwl™ and expansion of cloud-connected CPAP and monitoring devices, ResMed is at the forefront of consumerising diagnostic and therapeutic options.
• Digital Health Integration: Rapid uptake of connected care platforms, including AI-driven analytics and remote patient management, supports higher stickiness and recurring revenues.
• Acquisitions: The recent VirtuOx deal not only widens the product suite but also strengthens the company’s clinical data ecosystem, feeding into global market expansion and service scalability.
• Favourable Industry Trends: Philips’ protracted recovery from its recall continues to drive patient and clinical loyalty to ResMed, which has substantially consolidated its position in both established and emerging markets.
• Regulatory and ESG Leadership: Continued investment in compliance and sustainability initiatives pressures competitors and appeals to ESG-focused investors.
• Demographic Tailwinds: The rising incidence of sleep disorders, linked to ageing populations and increased health awareness, underpins a durable foundation for volume and margin expansion.

Analysts project continued high single-digit revenue growth, and given the market’s relatively underpenetrated status (with over 2.3 billion people globally suffering from sleep and breathing disorders), ResMed is advantageously exposed to long-term secular demand.

Investment Strategies

• Short-Term: For tactical traders, buying above the $237–$240 support zone with clear stops enables participation in potential resistance breakouts towards $252–$257.
• Medium-Term: Investors seeking momentum exposure can capitalise on trend confirmation as technicals and fundamentals become further aligned—particularly ahead of the upcoming Q4 earnings release and subsequent product launch cycles.
• Long-Term: For those with a longer horizon, ResMed’s ongoing innovation cycle, digital health integration, and capacity for structural growth make it a compelling addition to core healthcare and technology portfolios. Strategic acquisition and evolving addressable markets only add to the appeal.

Positioning now, at a period when the stock is clearing pivotal resistance and is well-supported by earnings momentum, seems to represent an excellent opportunity to benefit from potential re-rating and sector outperformance.

Is It the Right Time to Buy ResMed?

On balance, ResMed’s profile in May 2025 is that of a sector leader reinvigorating its growth narrative. Key strengths—stellar financial results, margin expansion, product and geographic diversification, and digital health leadership—converge with a highly supportive technical backdrop and dynamic volume patterns. Near-term catalysts such as the VirtuOx integration, new product launches, and ongoing demand tailwinds from both clinical and consumer health trends set the stage for further performance.

While competition from Philips and regulatory oversight remain factors to monitor, ResMed’s entrenchment in the global sleep and respiratory care market, combined with its balance sheet strength and culture of innovation, make a compelling case for renewed investor interest. In sum, the fundamentals and market context together justify the consideration of ResMed as a prime candidate for portfolios seeking exposure to forward-looking healthcare technology growth.

For investors searching for robust, innovation-led growth and resilient margins in a rapidly expanding sector, ResMed’s current positioning and trajectory may well mark the onset of a promising new bullish phase. This is a moment when ResMed seems poised to unlock significant shareholder value, meriting close attention from both seasoned and emerging investors alike.

How to buy Resmed stock in Australia?

Buying ResMed stock online is straightforward and secure when you use a regulated broker licensed in Australia. You have two primary options: purchasing actual shares (spot buying) or trading derivatives known as Contracts for Difference (CFDs). Both methods let you gain exposure to ResMed’s performance with just a few clicks, each with their own characteristics in terms of risk, cost, and strategy. To help you decide which method suits you best, you’ll find a detailed comparison of leading brokers further down the page.

Spot Buying

When you purchase ResMed stock as a cash investment (“spot buying”), you become a direct shareholder in the company. You’ll own the actual shares, receive any dividends paid, and benefit from long-term capital appreciation. In Australia, most brokers charge a fixed commission per trade, typically around AUD $5–$10 per order.

Important information

Example: With ResMed’s share price at approximately USD $239.95 (around AUD $365 at an exchange rate of 1 USD = 1.52 AUD), a AUD $1,000 investment allows you to buy about 2 shares (AUD $730 total), factoring in a brokerage fee of AUD $5. The remaining AUD $265 can be used for an additional fractional share if allowed, or kept as cash.

✔️ Gain Scenario: If the share price rises by 10%, your holding increases in value to AUD $803.
Result: That’s a AUD $73 gross gain—+10% on your initial investment (excluding minor currency fluctuations).

Trading via CFD

CFD (Contract for Difference) trading lets you speculate on the price movement of ResMed shares without owning the underlying stock. With CFDs, you can use leverage (borrowed funds), amplifying both gains and losses. Typical costs include the “spread” (the difference between the buy and sell price) and any overnight financing fees if you hold positions for more than a day.

Important information

Example: You open a CFD trade on ResMed with AUD $1,000, applying 5x leverage. This gives you exposure to AUD $5,000 worth of shares.

✔️ Gain Scenario: If ResMed’s share price climbs by 8%, your position profits by 8% × 5 = 40%.
Result: That’s a AUD $400 gain on your AUD $1,000 stake—before fees and charges.

Final Advice

Before you invest, it’s essential to compare brokerage fees, market access, and trading conditions to choose the best service for your needs. Your choice between spot buying and CFDs should reflect your investment goals and risk appetite. For a detailed comparison of regulated Australian brokers and more practical tips, consult our comparison table further down the page. Remember, investing puts your capital at risk—always consider what approach best fits your strategy.

Application

Notes

Learn More

#1

CFD Specialist

#1Recommended Offer

Avatrade

Notes

4.9

Discover

20% Deposit Bonus

5 things to know about Avatrade

Is AvaTrade reliable?

AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.

Why choose AvaTrade?

AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.

What are the fees at AvaTrade?

AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.

Who is AvaTrade for?

AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.

Is AvaTrade reliable?

AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.

Why choose AvaTrade?

AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.

What are the fees at AvaTrade?

AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.

Who is AvaTrade for?

AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.

#2

CFD and Indices Expert

#2

IG

Notes

4.8

Discover

74% of CFD accounts lose money. Risk limited to your capital.

5 things to know about IG

Is IG reliable?

IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.

Why choose IG?

IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.

What are the fees at IG?

IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.

Who is IG for?

IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.

Is IG reliable?

IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.

Why choose IG?

IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.

What are the fees at IG?

IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.

Who is IG for?

IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.

#3

30+ million users

#3

eToro

Notes

4.6

On the broker's website

5 Things to Know About eToro

Is eToro reliable?

Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.

Why choose eToro?

With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.

What are the fees at eToro?

eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).

Who is eToro for?

eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).

Is eToro reliable?

Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.

Why choose eToro?

With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.

What are the fees at eToro?

eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).

Who is eToro for?

eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).

Our 7 tips for buying Resmed stock

The latest news about Resmed

ResMed's Q3 FY2025 results showcased robust growth, surpassing revenue and earnings forecasts. In the quarter ended March 2025, ResMed posted a revenue increase of 8% year-over-year (9% in constant currency), with net income growing 21% and earnings per share rising 22%, comfortably beating analyst expectations. The 140 basis point improvement in gross margin, along with operating cash flow reaching $579 million, underlines sustained operational efficiency. For Australian investors, this positive momentum is highly relevant, as ResMed is dual-listed on the ASX and is a major local healthcare employer, supporting domestic research and manufacturing capabilities.

Australian regulatory alignment and market leadership further strengthened ResMed’s position in the region. Recent commentary from the Australian Therapeutic Goods Administration (TGA) affirmed continued regulatory compliance for ResMed’s sleep and respiratory products, instilling confidence in both institutional and retail investors. ResMed’s dominant share—over 60%—of the local sleep apnea device market, combined with Philips’ ongoing gradual re-entry after its product recall, keeps ResMed at the forefront for Australian healthcare providers and payers, reinforcing demand stability.

The acquisition of VirtuOx expands ResMed’s diagnostic service offerings, including across Australia. With the completion of this transaction on May 1, 2025, ResMed gains key technology and digital platforms for at-home sleep diagnostic testing, a strategic fit for Australia’s largely rural and remote populations that benefit from decentralized, tech-enabled healthcare services. This acquisition is expected to further augment ResMed’s core and ancillary revenue streams in Australia, aligning with the federal government’s digital health aspirations.

Technical indicators signal continued bullish market sentiment on the ASX and globally for ResMed shares. Shares closed at $239.95, marking a 1.73% weekly gain and standing above all major moving averages, including the 50, 100, and 200-day lines. The Relative Strength Index (RSI) of 65.63 and positive MACD readings underscore investor optimism and rising institutional participation—notably mirrored on the ASX—while sustained volume and support levels above $237.70 provide a constructive technical backdrop.

ResMed’s continued emphasis on connected care, innovation, and Australian R&D partnerships supports its longer-term outlook. The company’s leadership in cloud-connected devices, support for local clinical trials, and publication of impactful research (such as the recent meta-analysis in The Lancet Respiratory Medicine) underpin its domestic value proposition. Ongoing collaboration with Australian universities and hospitals fuels innovations in sleep and respiratory health, translating into new product launches and enhanced patient outcomes, key for regulatory and market access success in the region.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.